LQDA stock price prediction starts from the last regular-session print. Liquidia closed at $30
},
{
“@type”: “Question”,
“name”: “Why did LQDA stock fall on September 30, 2026?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “LQDA fell from $70
},
{
“@type”: “Question”,
“name”: “Is Yutrepia the same medicine as Tyvaso?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Yutrepia and Tyvaso both deliver inhaled treprostinil. Tyvaso is United Therapeutics’ nebulized solution, and Tyvaso DPI is its dry powder. Yutrepia is Liquidia’s dry powder, made with PRINT particle engineering and approved by the FDA on May 23, 2025, for PAH and PH-ILD. The ‘327 patent is not a patent on the molecule. It covers a method of treating PH-ILD by inhaling treprostinil at set doses, which is why the label line is what the court decided.”
}
},
{
“@type”: “Question”,
“name”: “Who is Liquidia’s chief executive?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Roger Jeffs is chief executive of Liquidia. On September 30, 2026, he said the company disagrees with the ruling on claims 1 and 14, is prepared to appeal, and intends to ask the FDA to remove PH-ILD from the Yutrepia label. Michael Kaseta is chief operating officer and chief financial officer. United Therapeutics’ chief executive is Martine Rothblatt. Michael Benkowitz, president and chief operating officer, is the United executive who spoke on the ruling.”
}
}
]
}